FOLH1 and cancer: [177Lu]Lu-PSMA therapy, which targets prostate cancer cells with beta radiation via a molecular approach distinct from ARPI or taxane-based chemotherapy, has emerged as a pivotal component in the sequential treatment strategies for mCRPC due to its cancer-control efficacy.